ORA, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Andover MA United States (1985)

Organization Overview

First Clinical Trial
2005
NCT00223951
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

H. Jerome Crampton | Ophthalmic Research Associates, Andover, MA | Ophthalmic Research Associates, Inc. | Ophthalmic Research Associates, North Andover, MA | ORA, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cataract (Phase 3)

Conjunctivitis (Phase 4)

Conjunctivitis, Allergic (Phase 4)

Conjunctivitis, Inclusion (Phase 2)

Conjunctivitis, Viral (Phase 2)

Dry Eye Syndromes (Phase 4)

Erythema (Phase 3)

Eye Diseases (Phase 2)

Eye Infections (Phase 2)

Hyperemia (Phase 3)

Inflammation (Phase 3)

Keratoconjunctivitis (Phase 4)

Keratoconjunctivitis Sicca (Phase 4)

Rhinitis (Phase 4)

Rhinitis, Allergic (Phase 4)

Rhinitis, Allergic, Seasonal (Phase 2)

Signs and Symptoms (Phase 2)

Syndrome (Phase 3)

Uveitis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 64
  • # of Trial APIs: 47